Emapalumab is an interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis. Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma.
- Mechanism
- Curator reviewed · 5 references
Emapalumab acts by binding and neutralizing interferon-gamma. The specific interaction between emapalumab and interferon-gamma produces an inhibition in the interaction between interferon-gamma and its cognate receptor on T-cells which produces the neutralizing activity. It is important to consider that emapalumab inhibits both free and IFNGR1-bound interferon-gamma as well as the interaction with IFNGR1 and IFNGR2 at the cell surface.
The HLH condition is a hyperinflammatory status characterized by the overwhelming activation of normal T lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death. As part of the condition profile, there have been reports proving a massive overexpression of interferon-gamma which is thought to drive the immune hyperactivation leading to organ failure. This condition is usually developed and present the symptomatic profile within the first months or years of life. These symptoms consist of fever, enlarged liver or spleen and a lower number of blood cells..
- Primary indication
- Emapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.Curator reviewed · 2 structured indications
- Formula / weight
- C6430H9898N1718O2038S46 · 154400.0 Da
- First approval
- United States, 2018
- Also known as
- Emapalumab-Izsg · Emapalumab-lzsg
- Code names
- NI-0501
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Emapalumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account